Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer added to standard treatment for aluminum phosphide poisoning
IRCT20210720051946N7Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevelamer carbonate in Aluminium phosphide poisoning (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Patient outcome, Duration of hospitalization and 6 more. Started Mar 2024; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20210720051946N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210720051946N7.